Journal of Clinical Oncology
Articles in this Issue
Breaking the silence: Sexual quality of life in Moroccan women after gestational trophoblastic tumors—A cross-sectional study.
e24139 Background: Gestational trophoblastic tumors (GTTs) are rare gynecologic malignancies with excellent cure rates. Ho...
Investigating the extent of consensus among oncologists in treatment selection for NSCLC patients with co-occurring biomarkers.
e13727 Background: Literature demonstrates that non-actionable biomarkers (BMs) can co-occur with actionable ones in NSCLC...
A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P).
1021 Background: In DESTINY-Breast09 (NCT04784715), first-line (1L) T-DXd + P demonstrated durable responses, a near doubl...
Novel myeloma therapy utilization in digital health advocacy users: A large US cohort analysis of >1,500 patients.
11189 Background: Real-world data consistently demonstrates that access to novel myeloma therapies (CAR-T and Bispecific A...
Ivonescimab plus gemcitabine/cisplatin and stereotactic body radiotherapy as first-line treatment for advanced biliary tract cancer: A single-arm, open-label, phase II exploratory study.
e16170 Background: Although gemcitabine/cisplatin (GC) plus immunotherapy is now standard first-line treatment for advance...
Text-based electronic patient-reported outcome monitoring in oncology: A 180-day longitudinal analysis of symptom burden changes in 701 cancer patients.
11113 Background: Digital electronic patient-reported outcome (ePRO) systems promise to improve symptom management in onco...
Phase II clinical study of ACT001 combined with radiotherapy in newly diagnosed pediatric diffuse intrinsic pontine glioma.
2074 Background: Diffuse intrinsic pontine glioma (DIPG) is an extremely lethal type of malignant tumor in the central ner...
Cerebrospinal fluid biomarker profiling in patients with non–small cell lung cancer and leptomeningeal disease.
2026 Background: Cerebrospinal fluid (CSF) cytology remains the standard for diagnosing leptomeningeal disease (LMD) and m...
Treatment pathway utilization after endoscopic ultrasound in pancreatic cancer.
e16366 Background: Pancreatic malignancies, primarily pancreatic ductal adenocarcinoma (PDAC) with a smaller proportion of...
The burden of breast cancer among women aged ≥70 years: Global trends in DALYs and mortality by socio-demographic index, 1990–2023.
e12700 Background: Breast cancer remains a major public health concern with high morbidity and mortality worldwide, partic...
The role and mechanism of tertiary lymphoid structure and its associated B cells in the resistance of immune checkpoint inhibitor therapy in acral melanoma.
e14591 Background: Recently studies have suggested that TEX, TLS and B cells are associated with prognosis and sensitivity...
Fine-scaled genomic ancestry clusters to reveal population-specific cancer enrichments in the All of Us Research Program.
10514 Background: Specific populations exhibit known enrichments for certain cancers, such as breast cancer (BC) in Ashken...
An ongoing phase 1–2a study of EO1001, an oral brain-penetrant pan-ErbB inhibitor, in patients with advanced ErbB-driven solid tumors including CNS disease.
TPS8681 Background: Central nervous system (CNS) metastases and primary brain tumors remain a major cause of morbidity and...
Terminal admission phenotypes and inpatient mortality in gastrointestinal malignancies: A national analysis of U.S. hospitalizations, 2018–2023.
e23231 Background: Inpatient mortality in gastrointestinal (GI) malignancies is often reported as a binary outcome...
Whole-genome sequencing–based ctDNA testing for post-surgical monitoring and early detection of recurrence or progression in uterine cancer.
5623 Background: Reliance on clinicopathologic risk factors to guide adjuvant therapy in early-stage uterine cancer (UC) h...
Efficacy of surgical glove-compression therapy as a prevention of paclitaxel-induced peripheral neuropathy: Randomized controlled trial.
12131 Background: Paclitaxel is a common cause of chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting toxic...
Post-treatment recovery patterns among patients with early-stage cancer who develop taxane-induced peripheral neuropathy (TIPN): SWOG S1714 (NCT03939481).
12117 Background: The primary analysis of S1714 developed and validated a TIPN risk prediction model including 5 clinical...
Trends in ischemic stroke and ischemic heart disease-related mortality among patients with malignancies in the United States: A 25-year CDC-WONDER analysis (1999-2023).
11154 Background: Substantial advances in cancer screening, diagnostics, and therapeutic strategies have improved survival...
Noninvasive imaging biomarkers for survival risk stratification with tarlatamab in ES-SCLC.
8020 Background: Subsequent treatment for extensive-stage small cell lung cancer (ES-SCLC) following platinum-etoposide ch...
Phase I clinical trial evaluating dual-targeting CAR-T cells (KD-496) against CLDN18.2 and NKG2DL in advanced gastrointestinal cancers and pancreatic cancers.
4224 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has shown limited efficacy in gastrointestinal (GI) canc...
Characterizing early oncology Orphan Drug Designation activity following expansion of the Orphan Drugs Exclusion.
e23050 Background: The Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program’s (DPNP) Orphan Drug Exclusio...
Retrospective study of guideline concordance in cervical cancer screening surveillance by age, race, and ethnicity.
5525 Background: Nearly one in five new cervical cancer cases occur in individuals aged ≥ 65, with higher incidence among...
Machine learning (ML) model integrating cell death pathways as a prognostic and predictive biomarker for patients with melanoma.
9561 Background: Established regulated non-apoptotic cell death mechanisms, including ferroptosis, necroptosis, and pyropt...
Neoadjuvant adebrelimab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: A single-arm, phase II trial.
4090 Background: Neoadjuvant therapy is the standard treatment for patients with locally advanced resectable esophageal sq...
Overall survival (OS) in premenopausal ER+/PR+, HER2− breast cancer (BC) treated with endocrine therapy (ET) ± chemotherapy (CT): A National Cancer Database (NCDB) analysis.
519 Background: The comparative benefit of ET alone vs ET+CT in premenopausal women with stage I-III ER+/PR+, HER2- BC rem...